{"contentid": 488078, "importid": NaN, "name": "Novel cystic fibrosis option safe, but no sign of efficacy", "introduction": "Translate Bio stock fell by a quarter in pre-market trading on Thursday, after interim data from a small trial testing mRNA candidate MRT5005 in cystic fibrosis (CF) failed to impress.", "content": "<p>Translate Bio (Nasdaq: TBIO) stock fell by a quarter in pre-market trading on Thursday, after interim data from a small trial testing mRNA candidate MRT5005 in cystic fibrosis (CF) failed to impress.</p>\n<p>MRT5005 is the first clinical-stage prospect of its type to address the underlying cause of CF through a unique mechanism of action.</p>\n<p>Importantly, the Phase I/II study showed that repeat dosing of MRT5005 was generally safe and well tolerated, with no serious adverse events.</p>\n<p>However, investors will be disappointed to see that there was no observed pattern of increased lung function as of yet.</p>\n<p>Translate said the data supported advancement of mRNA therapeutics for pulmonary diseases, and that it would keep working to &ldquo;optimize future clinical development&rdquo; of both MRT5005 and &ldquo;a next-generation CF candidate.&rdquo;</p>\n<p>The firm said that its next-generation CF discovery program has generated positive pre-clinical data and that investigational new drug (IND)-enabling studies would kick off in the second half of 2021.</p>\n<h2>Focus on Sanofi collab</h2>\n<p>While Translate Bio&rsquo;s work in pulmonary diseases has potential, analysts are also looking to the US biotech&rsquo;s collaboration and license agreement with French pharma major Sanofi (Euronext: SAN) as a source of future value.</p>\n<p>Building on an existing 2018 collaboration, the firms agreed in mid-2020 to work together on the development of mRNA vaccines across all infectious disease areas.</p>\n<p>As a consequence, Translate Bio received $425 million upfront, and became eligible for $1.9 billion in potential milestone payments, plus royalties on sales.</p>\n<p>Commenting on the latest trial data, chief executive Ronald Renaud said it was &ldquo;the first time messenger RNA encoding CFTR has been administered to patients with cystic fibrosis through inhaled repeat doses.&rdquo;</p>\n<p>Chief medical officer Ann Barbier said: &ldquo;Based on the first and second interim analyses, we believe we have achieved a safety profile that supports repeat dosing of inhaled mRNA and further advancement of the pulmonary platform for chronic dosing.&rdquo;</p>", "date": "2021-03-18 12:29:00", "meta_title": NaN, "meta_keywords": "cystic, fibrosis, Translate, data, mRNA, candidate, interim, trial, safe, efficacy, sign, option, Thursday, trading, pre-market, quarter, fell, stock, smal", "meta_description": "Translate Bio stock fell by a quarter in pre-market trading on Thursday, after interim data from a small trial testing mRNA candidate MRT5005 in cystic fibrosis", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-18 12:26:55", "updated": "2021-03-18 12:42:12", "access": NaN, "url": "https://www.thepharmaletter.com/article/novel-cystic-fibrosis-option-safe-but-no-sign-of-efficacy", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "2020_biotech_lab_vial_research_big.jpg", "image2id": "2020_biotech_lab_vial_research_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Cell and Gene Therapy, Respiratory and Pulmonary, Vaccines", "topic_tag": "Drug Trial, Research", "geography_tag": "USA", "company_tag": "Sanofi, Translate Bio", "drug_tag": "MRT5005", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-18 12:29:00"}